• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: W. L. GORE & ASSOCIATES, INC. GORE VIABAHN ENDOPROSTHESIS WITH HEPARIN BIOACTIVE SURFACE; STENT, SUPERFICIAL FEMORAL ARTERY

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

W. L. GORE & ASSOCIATES, INC. GORE VIABAHN ENDOPROSTHESIS WITH HEPARIN BIOACTIVE SURFACE; STENT, SUPERFICIAL FEMORAL ARTERY Back to Search Results
Catalog Number VBH070502W
Device Problem Adverse Event Without Identified Device or Use Problem (2993)
Patient Problem Perforation (2001)
Event Date 08/11/2020
Event Type  Injury  
Manufacturer Narrative
A review of the boxing records indicated the lot met all pre-release specifications.The device remains implanted, so evaluation of the actual device was unable to be completed.Images are available, and an imaging evaluation is in progress.
 
Event Description
The following was reported to gore: on (b)(6) 2020, a patient was implanted with a 7mm x 5cm gore® viabahn® endoprosthesis with heparin bioactive surface to treat abdominal aortic aneurysm with fenestration technique.After the viabahn device was advanced to renal artery and distal positioning, the physician withdrew the sheath and deployed the viabahn device.During deploying, it was found the viabahn device was shortened.Then angiography showed that the fenestration overlap between the viabahn device and aortic graft was not enough, resulting in serious endoleak.On (b)(6), another 7mm x 5cm viabahn device was used to cover endoleak.The endoleak disappeared after angiography.The patient tolerated the procedure.
 
Manufacturer Narrative
H6-3221: the images received cannot be used to perform a full imaging evaluation because they do not meet the dicom standard.The extent and accuracy of the observations and findings may be limited due to the completeness, format and/or quality of the images provided for review.Gore cannot guarantee the images provided are complete, accurate or lack alteration.Therefore, gore cannot guarantee all key findings have been captured or that the findings are accurate.The evaluation summary: one movie captured on a non-medical device, of an angiogram run on a monitor, received for evaluation.No name or full date can be visualized on images submitted.No lengths can be taken on angiogram imaging.The device implanted in what appears to be the aorta, is not a gore® device.There appears to be a stent in a possible visceral vessel.Cannot confirm a shortened device post deployment.There appears to be contrast outside the implanted devices.Cannot confirm device overlap or lack of, with available imaging.Endoleak of unknown origin.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
GORE VIABAHN ENDOPROSTHESIS WITH HEPARIN BIOACTIVE SURFACE
Type of Device
STENT, SUPERFICIAL FEMORAL ARTERY
Manufacturer (Section D)
W. L. GORE & ASSOCIATES, INC.
1505 n. fourth street
flagstaff AZ 86004
MDR Report Key10558222
MDR Text Key207700747
Report Number2017233-2020-01273
Device Sequence Number1
Product Code NIP
Combination Product (y/n)Y
PMA/PMN Number
P040037
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type user facility
Type of Report Initial,Followup
Report Date 10/19/2020
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator Health Professional
Device Expiration Date11/25/2022
Device Catalogue NumberVBH070502W
Was Device Available for Evaluation? No
Initial Date Manufacturer Received 08/25/2020
Initial Date FDA Received09/20/2020
Supplement Dates Manufacturer Received08/25/2020
Supplement Dates FDA Received10/18/2020
Is This a Reprocessed and Reused Single-Use Device? No
Patient Sequence Number1
Patient Outcome(s) Required Intervention;
Patient Age57 YR
-
-